Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Lucira Health, Inc. completed a disposition involving Pfizer Inc. for approximately $36.4 million (closed 2023-04-20).
- Action
- disposition
- Counterparty
- Pfizer Inc.
- Consideration
- approximately $36.4 million
- Closing
- 2023-04-20
Exact text from the filing
19, 2023, the Bankruptcy Court entered an order approving the sale of substantially all of the Company’s assets to the Buyer pursuant to the Purchase Agreement for approximately $36.4 million, which is comprised of a combination of cash, payments of Cure Costs to counterparties to assigned contracts and leases, and assumed or otherwise satisfied liabilities (the
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Lucira Health, Inc. amended Amendment to Asset Purchase Agreement with Pfizer Inc. (effective 2023-04-18).
- Action
- amendment
- Agreement
- asset purchase
- Counterparty
- Pfizer Inc.
- Effective
- 2023-04-18
Exact text from the filing
On April 18, 2023, the Company entered into an Amendment to Asset Purchase Agreement (the “Amendment”) with the Buyer that amended the Asset Purchase Agreement by and between the Company and the Buyer, dated April 12, 2023 (the “Original Purchase Agreement,” and as amended by the Amendment, the “Purchase Agreement”). The Amendment amended the Original Purchase Agreement to, among other things, (i) update the consideration and payment section to specify a fixed dollar amount of $6.5 million for the aggregate amount to be paid to cure any defaults (the “Cure Costs”) under each of the Jabil Contracts (as defined in the Purchase Agreement) and (ii) add an additional cash payment of $10.4 million less the aggregate amount of Cure Costs paid, satisfied or resolved by the Buyer in connection with certain other contracts as described therein.
View on SEC.gov